In December 2019 a new kind of virus was identified in China as the responsible of severe acute respiratory syndrome (SARS) and interstitial pneumonia. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) quickly spread around the world and in February 2020 became a pandemia in Europe. No pharmacological treatment is actually licensed for the SARS-CoV2 infection and at the current state of art there is a lack of data about the clinical management of the coronavirus 2019 disease (COVID-19). The aim of this observational study is to collect the data and the outcomes of COVID-19 patients admitted in the H. Sacco Respiratory Unit treated according to the Standard Operating Procedures and the Good Clinical Practice.
All consecutive adult COVID-19 patients admitted to our Respiratory Unit will be enrolled.
All demographic, anthropometric, laboratory, radiological, clinical and microbiological data
will be collected and analyzed according to the primary and secondary outcomes (see the
dedicated section).
During the hospitalization, patients will be treated according to the standard operating
procedure of our Respiratory Unit, such as arterial gas analysis, Rx, pharmacological
treatment, ventilation. This study is purely observational and no randomization will be
performed.
After discharge, patients a 7 days, 30 days and 6 months follow up will be assessed.
Other: standard operating procedures
standard operating procedures represented by continuous positive airway pressure (CPAP) therapy or non invasive ventilation, pharmacological treatment as antiviral and antibiotic drugs, bronchodilators, xanthines, enteral nutrition, hydration.
Inclusion Criteria:
- Patients that can give written or oral informed consent
- patients with microbiological diagnosis (i.e. rhinopharyngeal swab) of SARS-CoV2
infection
Exclusion Criteria:
- severe cognitive impairment
- absolute contraindication to non invasive ventilation or cpap therapy
- rhinopharyngeal swab negative for SARS-CoV2
Luigi Sacco University Hospital
Milan, Lombardia, Italy
Investigator: Pierachille Santus, MD, PhD
Contact: 0239042801
pierachille.santus@unimi.it
Investigator:
Pierachille Santus, MD, PhD
+390239042801
pierachille.santus@unimi.it
Elisa Franceschi, MD
+390239042277
elisa.franceschi@unimi.it